Population pharmacokinetics of antipsychotics

Kristin L. Bigos, Robert R. Bies, Stephen R. Marder, Bruce G. Pollock

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Response to antipsychotics is highly variable, which may be due in part to differences in drug exposure. The CATIE trials reported overall high rates of discontinuation due to lack of efficacy and/or intolerable side effects for all antipsychotics. Overall, 74% of patients with schizophrenia (SZ) discontinued the study medication before 18 months; 64% of those assigned to olanzapine, 75% of those assigned to perphenazine, 82% of those assigned to quetiapine, 74% of those assigned to risperidone, and 79% of those assigned to ziprasidone. Similarly, the majority of patients with Alzheimer's disease (AD) discontinued their assigned treatment, and in fact the adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation. In the AD trial, there were no significant differences among treatments with regard to the time to discontinuation of treatment for any reason: olanzapine (median, 8.1 weeks), quetiapine (5.3 weeks), risperidone (7.4 weeks), and placebo (8.0 weeks). One reason for the high rates of discontinuation may relate to the wide variability in the pharmacokinetics of these drugs, which often results in differences in the pharmacodynamics, both in the response to a drug and the incidence of adverse effects. For example, if a patient clears a drug faster than average, they will experience lower drug levels and may not respond as well at the same dose.

Original languageEnglish (US)
Title of host publicationAntipsychotic Trials in Schizophrenia
Subtitle of host publicationThe CATIE Project
PublisherCambridge University Press
Pages267-280
Number of pages14
ISBN (Electronic)9780511712265
ISBN (Print)9780521895330
DOIs
StatePublished - Jan 1 2010

Fingerprint

Antipsychotic Agents
olanzapine
Pharmacokinetics
Risperidone
Pharmaceutical Preparations
Population
Alzheimer Disease
Substance-Induced Psychoses
Perphenazine
Therapeutics
Aggression
Schizophrenia
Placebos
Incidence
Quetiapine Fumarate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bigos, K. L., Bies, R. R., Marder, S. R., & Pollock, B. G. (2010). Population pharmacokinetics of antipsychotics. In Antipsychotic Trials in Schizophrenia: The CATIE Project (pp. 267-280). Cambridge University Press. https://doi.org/10.1017/CBO9780511712265.016

Population pharmacokinetics of antipsychotics. / Bigos, Kristin L.; Bies, Robert R.; Marder, Stephen R.; Pollock, Bruce G.

Antipsychotic Trials in Schizophrenia: The CATIE Project. Cambridge University Press, 2010. p. 267-280.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bigos, KL, Bies, RR, Marder, SR & Pollock, BG 2010, Population pharmacokinetics of antipsychotics. in Antipsychotic Trials in Schizophrenia: The CATIE Project. Cambridge University Press, pp. 267-280. https://doi.org/10.1017/CBO9780511712265.016
Bigos KL, Bies RR, Marder SR, Pollock BG. Population pharmacokinetics of antipsychotics. In Antipsychotic Trials in Schizophrenia: The CATIE Project. Cambridge University Press. 2010. p. 267-280 https://doi.org/10.1017/CBO9780511712265.016
Bigos, Kristin L. ; Bies, Robert R. ; Marder, Stephen R. ; Pollock, Bruce G. / Population pharmacokinetics of antipsychotics. Antipsychotic Trials in Schizophrenia: The CATIE Project. Cambridge University Press, 2010. pp. 267-280
@inbook{ccb785b0831548ae9b31293b6078c167,
title = "Population pharmacokinetics of antipsychotics",
abstract = "Response to antipsychotics is highly variable, which may be due in part to differences in drug exposure. The CATIE trials reported overall high rates of discontinuation due to lack of efficacy and/or intolerable side effects for all antipsychotics. Overall, 74{\%} of patients with schizophrenia (SZ) discontinued the study medication before 18 months; 64{\%} of those assigned to olanzapine, 75{\%} of those assigned to perphenazine, 82{\%} of those assigned to quetiapine, 74{\%} of those assigned to risperidone, and 79{\%} of those assigned to ziprasidone. Similarly, the majority of patients with Alzheimer's disease (AD) discontinued their assigned treatment, and in fact the adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation. In the AD trial, there were no significant differences among treatments with regard to the time to discontinuation of treatment for any reason: olanzapine (median, 8.1 weeks), quetiapine (5.3 weeks), risperidone (7.4 weeks), and placebo (8.0 weeks). One reason for the high rates of discontinuation may relate to the wide variability in the pharmacokinetics of these drugs, which often results in differences in the pharmacodynamics, both in the response to a drug and the incidence of adverse effects. For example, if a patient clears a drug faster than average, they will experience lower drug levels and may not respond as well at the same dose.",
author = "Bigos, {Kristin L.} and Bies, {Robert R.} and Marder, {Stephen R.} and Pollock, {Bruce G.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1017/CBO9780511712265.016",
language = "English (US)",
isbn = "9780521895330",
pages = "267--280",
booktitle = "Antipsychotic Trials in Schizophrenia",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Population pharmacokinetics of antipsychotics

AU - Bigos, Kristin L.

AU - Bies, Robert R.

AU - Marder, Stephen R.

AU - Pollock, Bruce G.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Response to antipsychotics is highly variable, which may be due in part to differences in drug exposure. The CATIE trials reported overall high rates of discontinuation due to lack of efficacy and/or intolerable side effects for all antipsychotics. Overall, 74% of patients with schizophrenia (SZ) discontinued the study medication before 18 months; 64% of those assigned to olanzapine, 75% of those assigned to perphenazine, 82% of those assigned to quetiapine, 74% of those assigned to risperidone, and 79% of those assigned to ziprasidone. Similarly, the majority of patients with Alzheimer's disease (AD) discontinued their assigned treatment, and in fact the adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation. In the AD trial, there were no significant differences among treatments with regard to the time to discontinuation of treatment for any reason: olanzapine (median, 8.1 weeks), quetiapine (5.3 weeks), risperidone (7.4 weeks), and placebo (8.0 weeks). One reason for the high rates of discontinuation may relate to the wide variability in the pharmacokinetics of these drugs, which often results in differences in the pharmacodynamics, both in the response to a drug and the incidence of adverse effects. For example, if a patient clears a drug faster than average, they will experience lower drug levels and may not respond as well at the same dose.

AB - Response to antipsychotics is highly variable, which may be due in part to differences in drug exposure. The CATIE trials reported overall high rates of discontinuation due to lack of efficacy and/or intolerable side effects for all antipsychotics. Overall, 74% of patients with schizophrenia (SZ) discontinued the study medication before 18 months; 64% of those assigned to olanzapine, 75% of those assigned to perphenazine, 82% of those assigned to quetiapine, 74% of those assigned to risperidone, and 79% of those assigned to ziprasidone. Similarly, the majority of patients with Alzheimer's disease (AD) discontinued their assigned treatment, and in fact the adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation. In the AD trial, there were no significant differences among treatments with regard to the time to discontinuation of treatment for any reason: olanzapine (median, 8.1 weeks), quetiapine (5.3 weeks), risperidone (7.4 weeks), and placebo (8.0 weeks). One reason for the high rates of discontinuation may relate to the wide variability in the pharmacokinetics of these drugs, which often results in differences in the pharmacodynamics, both in the response to a drug and the incidence of adverse effects. For example, if a patient clears a drug faster than average, they will experience lower drug levels and may not respond as well at the same dose.

UR - http://www.scopus.com/inward/record.url?scp=84910064902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910064902&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511712265.016

DO - 10.1017/CBO9780511712265.016

M3 - Chapter

AN - SCOPUS:84910064902

SN - 9780521895330

SP - 267

EP - 280

BT - Antipsychotic Trials in Schizophrenia

PB - Cambridge University Press

ER -